N@N

Market Maker Surveillance Report. XLE, XLK, INTC, ISPH, RRD, SNY, Bullishly Biased Price Friction For Tuesday, April 5th 2011

^{Published on 2011-04-05 17:51:19 - WOPRAI}
 

April 5, 2011 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 2573 companies with "abnormal" market making, 2747 companies with positive Friction Factors and 2601 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. ENERGY SELECT SECTOR SPDR (NYSE:XLE), TECHNOLOGY SELECT SECT SPDR (NYSE:XLK), INTEL CORP (NASDAQ:INTC), INSPIRE PHARMACEUTICALS INC (NASDAQ:ISPH), RR DONNELLEY & SONS CO (NASDAQ:RRD), SANOFI-AVENTIS-ADR (NYSE:SNY). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     XLE        $0.320       0.40%        8,538,073       44.25%       10,907,673      56.53%       -2,369,600      Abnormal
     XLK        $0.040       0.14%        3,663,313       36.93%       6,410,621       64.63%       -2,747,308      Abnormal
     INTC       $0.240       1.23%        29,648,415      47.49%       33,929,444      54.35%       -4,281,029      Abnormal
     ISPH       $0.980       24.62%       22,773,642      41.41%       32,182,604      58.51%       -9,408,962      Abnormal
     RRD        $0.140       0.74%        485,413         16.24%       2,494,884       83.47%       -2,009,471      Abnormal
     SNY        $0.280       0.78%        893,617         11.66%       6,624,894       86.45%       -5,731,277      Abnormal

For example, the chart above shows XLE with 2,369,600 greater shares of selling than buying (NetVol) and the stock price was up $0.32000. This means the Market Makers were trading the stock in a way inconsistent with normal supply and demand (Economics 101); more selling than buying should cause prices to drop.

ENERGY SELECT SECTOR SPDR (NYSE:XLE) - ENERGY SELECT SPD

TECHNOLOGY SELECT SECT SPDR (NYSE:XLK) - S&P TECHNOLOGY FUND

INTEL CORP (NASDAQ:INTC) - Intel Corporation designs, manufactures, and sells integrated circuits for computing and communications industries worldwide. It offers microprocessor products used in notebooks, netbooks, desktops, servers, workstations, storage products, embedded applications, communications products, consumer electronics devices, and handhelds. The company also offers system on chip products that integrate its core processing functionalities with other system components, such as graphics, audio, and video, onto a single chip. It also provides chipset products that send data between the microprocessor and input, display, and storage devices, such as keyboard, mouse, monitor, hard drive, and CD or DVD drives; motherboards that has connectors for attaching devices to the bus, and products designed for desktop, server, and workstation platforms; and wired and wireless connectivity products, including network adapters and embedded wireless cards used to translate and transmit data across networks. In addition, Intel offers NAND flash memory products primarily used in portable memory storage devices, digital camera memory cards, and solid-state drives; network processors used in networking equipment to manage and direct data moving across networks and the Internet; software products, including operating systems, middleware, and tools used to develop, run, and manage various enterprise, consumer, embedded, and handheld devices, as well as software development tools that enable the creation of applications; and healthcare products designed to connect people and information to improve patient care and safety. Further, it offers platforms that include a microprocessor, chipset, and enabling software. Intel sells its products primarily to original equipment manufacturers, original design manufacturers, PC and network communications products users, and other manufacturers of industrial and communications equipment. The company was founded in 1968 and is based in Santa Clara, California.

INSPIRE PHARMACEUTICALS INC (NASDAQ:ISPH) - Inspire Pharmaceuticals, Inc., a biopharmaceutical company, focuses on researching, developing, and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The company offers AzaSite, an azithromycin ophthalmic solution and topical anti-infective for the treatment of bacterial conjunctivitis; Elestat, an epinastine HCl ophthalmic solution and topical antihistamine for the prevention of ocular itching associated with allergic conjunctivitis; and Restasis, a cyclosporine ophthalmic emulsion for the treatment of dry eye disease. Its product candidates in clinical development include Denufosol tetrasodium for the treatment of cystic fibrosis, which is under phase III clinical trial; Prolacria for the treatment of dry eye disease, which is under phase III clinical trial; AzaSite for the treatment of blepharitis that is under phase II clinical trial; and Glaucoma product candidates, which are in phase I clinical trial. The company has an agreements with Allergan, Inc. to co-promote Elestat in the United States, as well as to develop and commercialize Restasis and Prolacria; a license agreement with InSite Vision Incorporated to commercialize AzaSite, as well as other topical anti-infective products containing azithromycin used in the treatment of human ocular or ophthalmic indications primarily in the United States and Canada; and a development, license, and supply agreement with Santen Pharmaceutical Co., Ltd. for the development of diquafosol tetrasodium for the therapeutic treatment of ocular surface diseases in Asia. Inspire Pharmaceuticals, Inc. was founded in 1993 and is based in Durham, North Carolina.

RR DONNELLEY & SONS CO (NASDAQ:RRD) - R.R. Donnelley & Sons Company provides pre-media, printing, logistics, and business process outsourcing products and services to private and public sectors worldwide. The company operates primarily in the commercial print portion of the printing industry, with related product and service offerings designed to offer customers solutions for communicating their messages to target audiences. Its products and related service offerings include magazines, catalogs, retail inserts, books, directories, financial print, direct mail, forms, labels, office products, statement printing, pre media, and logistics services. The company also offers business process outsourcing services that comprise transactional print and outsourcing services, statement printing, direct mail, and print management services; and product configuration, customized kitting, and order fulfillment for technology, medical device, and other companies. It distributes its products to end-users through the United States postal services, retail channels, electronically, or by direct shipment to customer facilities. R.R. Donnelley & Sons was founded in 1864 and is based in Chicago, Illinois.

SANOFI-AVENTIS-ADR (NYSE:SNY) - Sanofi-Aventis, a healthcare company, engages in the discovery, development, and distribution of therapeutic solutions to improve the lives of everyone. It offers a range of healthcare assets, including a broad-based product portfolio in prescription drugs, OTC/OTX, generics, vaccines, and animal health. The company also has exclusive worldwide license to develop, manufacture, and commercialize antibody drug conjugate (ADC) products for the treatment of cancer. Sanofi-Aventis has a strategic alliance with Scripps Genomic Medicine for the purpose of research and development initiatives in the field of individualized medicine; and with Avila Therapeutics, Inc. to discover targeted covalent drugs for the treatment of cancers, as well as a joint venture with Hangzhou Minsheng Pharmaceutical Group Co. Ltd. to develop non-prescription drugs in China. The company was founded in 1970 and is headquartered in Paris, France.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net